Assad SM
assadsm.bsky.social
Assad SM
@assadsm.bsky.social
Nephrologist @ CMC Vellore, India
Reposted by Assad SM

T3d
Benefits may vary, and results in the general population on CV risk and mortality are still
controversial.
Overall, the results of recent studies have been mixed results. Different study populations,
end points and dosing may account for the lack of clarity. #NephJC
December 3, 2025 at 2:43 AM
Hey I’m Assad, nephrologist working in a high-volume IgAN centre in India !
We’re still like the KDIGO guidleimes though - a bit outdated as we come up !
Probably it’s the cost of these drugs and their availability which limit us !
No COI
#NephJC
November 19, 2025 at 2:22 AM
Reposted by Assad SM
Ongoing late posts from @theisn.org #ISNWCN

from the high impact trial session - this was a great study design

The India ALLIANCE GRACE IgAN trial

Lead by Succeena Alexander from CMC Vellore

#NephSky
1/
February 16, 2025 at 2:51 PM
Reposted by Assad SM
These are the interventions:
- SoC alone
- Low dose steroids
- Gut directed (NOT targeted release) budesonide
- MMF
- Hydroxychloroquine
- later Finerenone once generic in India

Great choices!

#NephSky #ISNWCN
4/
February 16, 2025 at 2:51 PM
Reposted by Assad SM
Treatment in children: 👶💉
Management is based on RAS blockade, salt restriction, and blood pressure control. Glucocorticoids are used in those with persistent proteinuria or high-risk features, sometimes combined with cyclophosphamide in severe cases.

#NephJC
October 29, 2025 at 1:39 AM
Reposted by Assad SM
Yes my exact opinion, guidelines may be evolving and improving but what happens in reality?

Our patients either come with a creat of 8,
Or they’re loaded with steroids for quite long without even SGLT2i or ARBs many times, and they’re just victims of therapeutic misadventure.
Sorry state. #NephJC
October 29, 2025 at 1:58 AM
Hey this is S M Assad, Assistant Prof Nephrology from CMC Vellore !
#NephJC

In India, many with IgAN present late and do poorly—limited access, high costs, and low awareness keep outcomes far behind what they could be. Also the fact that the eGFR slope is somehow too deep.

No COI
October 29, 2025 at 1:04 AM
Hey this is Assad, nephrologist from Christian Medical College, Vellore in India.

We tend to restrict proteins in our patients, and they go a few steps further stopping all protein altogether - ending up cachexic. Change is warranted. Most of our patients are traditionally vegetarian too🥑
#NephJC
a man in a suit and tie is eating broccoli from a person 's hand .
ALT: a man in a suit and tie is eating broccoli from a person 's hand .
media.tenor.com
October 15, 2025 at 1:19 AM
Reposted by Assad SM
But I don’t see it going beyond the small privileged group of HLA matched patients !

There are too many IFs and BUTs involved
#NephJC
October 1, 2025 at 1:57 AM
Reposted by Assad SM
The problem here is that - as attractive as being IS free sounds - it comes with a huge load right from patient selection, ensuring HLA compatibility, putting a huge burden on donors (making the MDR 101) and a very high risk IS withdrawal trial - with risk of rejection for the KTRs #NephJC
October 1, 2025 at 1:59 AM
Reposted by Assad SM
This is a once-a-year plea for support #NephJC
If you want to support #NephJC
🍂🍂🍂Contribute to our Fall Pledge Drive 💰and get some cool merch. We only function because of you and appreciate all your donations to our work.
www.nephjc.com

October 1, 2025 at 1:34 AM
Hey, I'm S M Assad, young Nephrologist from CMC Vellore, India.
No COI.
While some centers in India have explored steroid-free regimens and local stem-cell work, the complexity and cost of bespoke cell therapies mean we rely on conventional, cost-effective IS as the standard of care. #NephJC
October 1, 2025 at 1:01 AM
Reposted by Assad SM
It was. The book is focuses on the history of TB, but it’s definitely not historical. In India, it’s our present. TB plagues all communities and classes, and it’s probably nothing to be proud of, that I seem to know and see most of these situations day-in and out !
#NephJC
August 20, 2025 at 2:08 AM
Reposted by Assad SM
On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
Mind The Gap: When eGFR Creatinine and Cystatin C Disagree — NephJC
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
www.nephjc.com
July 21, 2025 at 11:31 AM
Hi I’m Assad, practising nephrologist from India, Flozinator but not a finerator (yet) !
My first #NephJC chat !
No COI
July 9, 2025 at 1:30 AM
Reposted by Assad SM
Attended #KSN2025 in Seoul 🇰🇷! Presented two posters at the conference! 👩🏻‍⚕️
A scintillating experience soaking in all the science, savouries and Seoul skies !! 😃🎏🥋🍜@assadsm.bsky.social
#nephrology #KSN #seoul #nephroconference
June 23, 2025 at 10:12 AM
Attended @ksnmeeting 2025 at Seoul and had the opportunity to present my poster at the conference! Thrilled by the city’s vibrant cultural and modern landscape!!
@nephromommy-akshu.bsky.social

#nephrology #KSN #seoul #nephroconference
June 23, 2025 at 11:45 AM
Reposted by Assad SM
The class of 2025, #NephJC interns

www.nephjc.com/news/2025/6/...
June 21, 2025 at 2:04 PM
Reposted by Assad SM
Follow them all here: go.bsky.app/7qJxtg
June 21, 2025 at 2:04 PM
Reposted by Assad SM
Welcome next #NephJC generation! New NephJC authors & creators debuting in July 2025, check them out & give them a follow! 📸
Team A:
@sejalplakhani.bsky.social
@notjustdialysis.bsky.social
@msocomd.bsky.social
@shelliefravel.bsky.social
@salinesolut.bsky.social
@jeyakimarmeyyappan.bsky.social
June 11, 2025 at 1:58 AM